[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-related-problemcondition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-related-problemcondition":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,89,118,145,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100574087","decentralized-clinical-trial-of-effectiveness-of-energypoints-app-in-cancer-survivors-100574087",false,"NCT06754722","Decentralized Clinical Trial of Effectiveness of EnergyPoints App in Cancer Survivors","Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors","Inclusion Criteria:\n\n* Have cancer or have been treated for cancer;\n* at least a moderate level of fatigue (greater than 4 on a 0 to 10 Likert-type scale);\n* able to read and speak in English;\n* age 18 years or older; Android 11 or later),\n* adequate hearing, vision, and functional ability to see, hear and use the app and participate in interviews,\n* willing to wear a provided Fitbit 24\u002F7 (except when charging) throughout the study.\n\nExclusion Criteria:\n\n* recent history of easy bruising or bleeding\n* previous use of the EnergyPoints app.\n\nNote: The functional ability questions will exclude anyone who is too sick to participate due to life-limiting disease.","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of the study is to evaluate whether EnergyPoints, a mobile phone health app that guides the participant to do self-acupressure, can decrease fatigue and improve sleep. Acupressure consists of applying physical pressure with fingers or a device to small locations on the body called acupoints.\n\n* The investigators will conduct this clinical trial remotely, allowing participants to use the app wherever they are. Participation will involve using the app daily while wearing a fitness tracker (a Fitbit) on the wrist, answering questions on the app and online, as well as completing a questionnaire and participating in an online interview at the end of the study. Participants will be assigned by chance to one of two groups. In both groups, participants will have a 1 week baseline week (Week 0) to get used to the Fitbit. Participants in the Immediate Group will start the 6 week trial of EnergyPoints immediately (Week 1). Participants in the Wait-List Group will be on a wait-list for 6 weeks during which time they will wear the Fitbit and answer online questions daily and weekly. At the end of the waiting period (week 7), these participants will begin the 6 week trial of EnergyPoints.\n* The risks to participating are minimal. There is a small risk of bruising or getting sore at a point where participants apply pressure. As with any mobile app, there is the possibility that electronic information could be viewed by third parties not involved in the study. The investigators cannot promise any benefits from participating in the study. However, it is possible that using acupressure might improve fatigue or sleep. Participants may use any other approaches to improve fatigue and sleep while in the study.\n\nA pilot study will be conducted first with 8 participants and 1 week periods (1 week baseline, 1 week waitlist, and 1 week intervention followed by an End of Study Questionnaire and Exit Interview",[26,27,28,29],"Cancer-related Problem\u002FCondition","Fatigue in Cancer Survivors","Sleep Disturbances","Health-related Quality of Life",[31,32,33,34,35,36],"fatigue","sleep disturbances","acupressure","mobile health app","cancer survivors","cancer symptoms","RECRUITING","2026-04-05",{"date":40,"type":41},"2026-04-07","ACTUAL",{"date":43,"type":41},"2026-04-01",{"date":45,"type":20},"2027-12-31",{"name":47,"class":48},"5 Point App, Inc.","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100578269","home-monitoring-of-complete-blood-count-performed-by-patients---a-pilot-study-on-the-implementation-process-in-south-baltic-countries-100578269","NCT06809101","Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.","AMBeR eBlood","Inclusion Criteria:\n\n* legally competent patients\n* aged 18 or older\n* diagnosed with cancer (ICD-10: C00\\* - C97\\*)\n* enrolled at the Department of Oncology\u002FHematology for outpatients\n* participants who are willing and able to give informed consent for participation in the study\n* participants should receive chemotherapy in Daily Chemotherapy Unit and be within 4 weeks of chemotherapy initiation, and the expected duration of chemotherapy should be at least 12 weeks from inclusion\n\nExclusion Criteria:\n\n* inability to give informed consent due to mental capacity or language barrier\n* patient unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result\n* known bleeding disorder\n* bad circulation preventing the patient from getting enough blood drops to perform the test",{"count":58,"type":20},265,"OBSERVATIONAL","Introduction:\n\nThe number of diagnosed cancers is systematically increasing every year. Cancer patients need to undergo regular blood tests to monitor safety and eligibility for treatment. In case of poor blood results, the chemotherapy session must be omitted. For patients living far from the center, this means unnecessary travel with involvement of helpers, additional costs, increased potential of hospital acquired infections, and frustration associated with missed opportunity for treatment.\n\nAims:\n\nThe primary aim of this study is to gain knowledge about successful implementation of remote, home monitoring of complete blood count to cancer patients during and after systemic treatment for cancer. The secondary aim of the AMBeR collective study protocol is to pilot new technology, gain more context around future investigations and verify costs and changes in patient treatment pathways.\n\nMethodology:\n\nThe investigators will test implementation of home blood monitoring in three South Baltic Countries (DK, PL, GER). Each site will participate in the implementation study with study group á n=33 (total n=165) and control group n=20 (total n=100). The duration of the study is planned for 4 cycles of chemotherapy for each patient and a 3-month follow up period. The first cycle of learning and training at the Outpatient Daily Clinic, then the remaining 3 cycles of blood monitoring at home. The average cycle length is 21-30 days, number of measurements will be determined individually depending on the diagnosis. At a baseline, after 4 cycles of chemotherapy (12-16 weeks) and after a 3-month follow-up period, parallel studies will be carried out in both the study and control groups, using mixed methods the investigators will assess outcomes of reach, effectiveness, adoption, implementation and maintenance (RE-AIM).\n\nExpected benefits:\n\nImplementation of the AMBeR study should reduce the amount of unnecessary and nontherapeutic hospital visits and improve manageability and independence of the patients. The investigators believe that the decrease in the number of hospital visits will diminish the risk of infection for vulnerable individuals, as well as save costs for patients and hospitals. These factors will also translate into better logistics of chemotherapy units, decreased carbon-dioxide trail, and improved quality of life and patient empowerment.",[62,26,63,64,65,66],"Cancer","Chemotherapy","Chemotherapy-induced Neutropenia","Chemotherapy Induced Anaemia","Chemotherapy Induced Thrombocytopenia",[68,69,70,71,72,73,74,75,76,77],"home blood monitoring","complete blood count","cancer","chemotherapy","implementation","research","e-health","oncology","home-based","feasibility","2026-02-26",{"date":80,"type":41},"2026-02-27",{"date":82,"type":41},"2025-03-17",{"date":84,"type":20},"2027-03-31",{"name":86,"class":87},"Pomeranian Medical University Szczecin","OTHER",5,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":49},"100464865","phase-1-modafinil-to-improve-fatiguability-100464865","NCT05333250","Modafinil to Improve Fatiguability","Modafinil to Improve Fatiguability (MODIFY): Modafinil vs. Placebo Vanguard RCT","MODIFY","Inclusion Criteria:\n\n1. 18 years of age or older with stage III or IV cancer diagnosis\n2. Estimated prognosis ≥ 3 months\n3. Eastern Cooperative Oncology Group (ECOG) Score 0-2\n4. Experiencing cancer-related fatigue, defined as a score of 4 or greater on the Fatigue item of the Edmonton Symptom Assessment System-revised-constipation\u002Fsleep (ESAS-r-cs)\n5. Ability to understand and communicate in English\n6. Ability to give first-person informed consent\n\nExclusion Criteria:\n\n* Currently receiving or have received cytotoxic chemotherapy in the last 6 weeks\n* Allergy to modafinil or placebo contents\n* Dose change of prednisone or dexamethasone in the past 7 days or planned dose change during study period\n* Blood transfusion in the last 2 weeks\n* Hemoglobin lower than 80 g\u002FL measured in the last 4 weeks\n* TSH above normal range in the last 4 weeks\n* Severe liver dysfunction (total bilirubin \\>3x upper limit of normal, or aspartate aminotransferase or alanine aminotransferase \\>5x upper limit of normal)\n* Known brain metastasis or primary brain tumor\n* Documented dementia diagnosis\n* Documented major psychiatric illness including major depressive episode, bipolar disorder, schizophrenia\n* Uncontrolled hypertension as defined by a blood pressure greater than 140\u002F90mmHg\n* Unstable angina\n* Recent (\\\u003C6 months previous) myocardial infarction\n* Evidence of left ventricular hypertrophy or ischemia on ECG\n* Arrythmia (e.g., atrial fibrillation)\n* Coronary artery disease with Canadian Cardiovascular Society Symptoms Class \\>1\n* Taking high dose selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants\n* Taking any benzodiazepine at any dose\n* Taking any amphetamine at any dose\n* Taking any monoamine oxidase inhibitor (MAOI) at any dose\n* Taking any azole anti-fungal medication (e.g., fluconazole, itraconazole, or ketoconazole)\n* Taking any of the following medications at any dose:\n\n  1. Methylphenidate\n  2. Cyclosporine\n  3. Propranolol\n  4. Phenytoin\n  5. S-mephenytoin\n  6. Warfarin\n  7. Triazolam\n  8. Ethinyl estradiol\n  9. Clomipramine\n  10. Midodrine\n  11. Antipyrine\n* Inability to ingest oral capsule\n* Pregnancy or lactation, or trying to conceive\n* Any other history, condition, therapy, or uncontrolled intercurrent illness which could, in the opinion of the Qualified Medical Investigator, affect compliance with study requirements or which would make the participant unsuitable for this study.\n* Simultaneous participation in another interventional clinical study (e.g., Phase 1-3 clinical studies) or treatment with any investigational medicinal product within 30 days prior to screening visit that could, in the judgment of the Qualified Medical Investigator, affect the patient's participation in or outcome of this clinical trial.",{"count":98,"type":20},40,[100,101],"PHASE1","PHASE2","Cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) are among the most commonly reported disabling symptoms experienced by patients with advanced cancer. However, there are currently limited evidence-based pharmacologic interventions available. The investigators will conduct a Vanguard Randomized Clinical Trial (RCT) to estimate the effect of modafinil in managing CRF and CRCI, and to test the feasibility of carrying out the study.",[104,26,105],"Cancer-related Cognitive Difficulties","Fatigue",[62,105,107,108],"Cognitive Impairment","Modafinil","2026-01-09",{"date":111,"type":41},"2026-01-13",{"date":113,"type":20},"2026-01-22",{"date":115,"type":20},"2028-03",{"name":117,"class":87},"Ottawa Hospital Research Institute",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":49},"100580630","effect-of-cognitively-challenging-physical-activity-on-executive-functions-in-pediatric-cancer-patients-100580630","NCT06839794","Effect of Cognitively Challenging Physical Activity on Executive Functions in Pediatric Cancer Patients","An Investigator Initiated, Non-randomized Controlled Trial on the Effect of Cognitively Challenging Physical Activity on Executive Functions in Paediatric Cancer Patients","KiKli Fit","Inclusion Criteria:\n\n* Written informed consent of parents \u002F legal guardian and participants, where applicable\n* Diagnosis of any type of cancer requiring chemo- and\u002For radiotherapy, or CNS surgery, expected to last a minimum of at least 6 weeks at the time of recruitment\n* Age: 6-17.99 years at time of recruitment\n\nExclusion Criteria:\n\n* Cognitive and physical disabilities that prevent participation in the intervention.\n* Inability to follow the procedures of the study, e.g. due to language problems.\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.\n* Denied written informed consent from participants.","6 Years","17 Years",{"count":129,"type":20},70,[23],"When it comes to exercise and sport for children and adolescents with cancer, there is often still the opinion that physical activity has a negative effect on the weakened body suffering from cancer. Many studies show that the opposite is the case: physical activity for children and adolescents with cancer do not jeopardise the success of treatment, but rather promote it. It has been shown that physical activity has a positive effect on motor skills, physical fitness, sleep quality, fatigue symptoms, body image and general quality of life in children and adolescents with cancer.\n\nIn addition, physical activity leads to an improved fat-to-muscle ratio, metabolic status, bone strength and reduces cardiovascular disease. Furthermore, various studies show that oncological patients with sarcopenia (loss of muscle mass) and frailty have a poorer response to their cancer therapy. This broad spectrum of effects of physical activity leads to improved and faster rehabilitation, is directly linked to the success of treatment and has led to exercise being an integral part of treatment in many paediatric oncology centres worldwide.\n\nFurthermore, more exercise that includes playful cognitive tasks is expected to lead to improved attention, memory and academic achievement. Besides, it is important to try to get children to exercise at home outside of the inpatient setting. Hybrid (on-site and digital meetings) programmes also work for children and adolescents. Additionally, the research project offers sports counselling after the end of therapy to reintegrate the patients into everyday sporting life, be it in a club or at school.\n\nThe central question of the research project is: Does cognitive challenging physical activity developed for children and adolescents undergoing acute cancer therapy improve cognitive and motor performance compared to a control group receiving standard care?",[133,26,134,135],"Childhood Cancer","Cognitive Side Effects of Cancer Therapy","Physical Activity","2025-08-11",{"date":138,"type":41},"2025-08-12",{"date":140,"type":41},"2025-05-10",{"date":142,"type":20},"2028-12-01",{"name":144,"class":87},"University of Bern",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100571202","cancer-and-aging-research-group-carg-chemotherapy-toxicity-risk-scores-in-older-adults-with-cancer-in-china-100571202","NCT06717178","Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores in Older Adults With Cancer in China","Correlation of the Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores and Unplanned Hospitalizations in Older Cancer Patients--A Multi-center Prospective Cohort Study","Inclusion Criteria:\n\n* Age≥ 70 years old\n* Confirmed diagnosis of solid tumor (any stage)\n* ECOG-PS score 0-2 points\n* Admission to the hospital for a new chemotherapy regimen (initial or change)\n* Patients need to have the ability to read and write, or communicate in Chinese\n* The patient must have the ability to give informed consent.\n\nExclusion Criteria:\n\n* Patients who are on immunotherapy and\u002For targeted therapy only\n* Patients with hematologic malignancy\n* Patients with severe infections (sepsis, severe respiratory tract infections, severe urinary tract infections, severe abdominal infections, etc.).\n* Patients with severe heart, liver, and kidney dysfunction or failure","70 Years",{"count":154,"type":20},322,"The goal of this observational study is to learn about the impact of chemotherapy-related toxicity on older cancer patients in China. The main question it aims to answer is:\n\nDoes the Cancer and Aging Research Group (CARG) chemotherapy toxicity risk score predict chemotherapy-related toxicity in Chinese cancer patients over age 70? Participants over age 70 on systemic chemotherapy will answer questions listed in the CARG chemotherapy toxicity risk tool.",[62,26],[62,158,159],"Toxicity","Geriatric","2025-04-01",{"date":162,"type":41},"2025-04-02",{"date":164,"type":41},"2024-12-24",{"date":166,"type":20},"2025-12-31",{"name":168,"class":87},"RenJi Hospital",2,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":49},"100481264","icanwork-a-randomized-controlled-trial-100481264","NCT05546736","iCanWork: A Randomized Controlled Trial","Effects of the iCanWork Intervention to Improve Cancer Survivors' Experience With Return to Work: A Randomized Controlled Trial (RCT)","iCanWork","Inclusion Criteria:\n\n* diagnosed with cancer (all types) treated with curative intent and of working age (between 18 and 65 at the time of diagnosis)\n* gainfully employed at the time of diagnosis (full or part-time, including students)\n* still on sick leave, including long-term disability leave, but for less than 2 years\n* has not started to return to work, since stopping due to cancer\n* can read and understand English or French\n* reside in Canada.\n\nExclusion Criteria:\n\n\\- If the cancer survivor's physicians consider returning to work unwise, such as due to a metastatic cancer diagnosis","65 Years",{"count":180,"type":20},270,[23],"The aim of this study is to evaluate the effectiveness of the iCanWork intervention in assisting cancer survivors (CS) to return to work (RTW) and its impact on their health-related quality of life (QoL), health service utilization, RTW readiness, time to RTW, and work capacity.",[26,184,185],"Survivorship","Quality of Life",[187,35,188,189],"return to work","vocational rehabilitation","randomized controlled trial","NOT_YET_RECRUITING","2022-09-22",{"date":193,"type":41},"2022-09-26",{"date":195,"type":20},"2023-04-01",{"date":197,"type":20},"2026-09-01",{"name":199,"class":87},"McGill University"]